Global Human Prothrombin Complex Market Growth 2023-2029

Global Human Prothrombin Complex Market Growth 2023-2029

Prothrombin complex concentrate (PCC), also known as factor IX complex, is a medication made up of blood clotting factors II, IX, and X. Some versions also contain factor VII. It is used to treat and prevent bleeding in hemophilia B if pure factor IX is not available.
LPI (LP Information)' newest research report, the “Human Prothrombin Complex Industry Forecast” looks at past sales and reviews total world Human Prothrombin Complex sales in 2022, providing a comprehensive analysis by region and market sector of projected Human Prothrombin Complex sales for 2023 through 2029. With Human Prothrombin Complex sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human Prothrombin Complex industry.
This Insight Report provides a comprehensive analysis of the global Human Prothrombin Complex landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Human Prothrombin Complex portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Human Prothrombin Complex market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human Prothrombin Complex and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human Prothrombin Complex.
The global Human Prothrombin Complex market size is projected to grow from US$ 1542.7 million in 2022 to US$ 3462.1 million in 2029; it is expected to grow at a CAGR of 3462.1 from 2023 to 2029.
Global Human Prothrombin Complex key players include Octapharma, Shire, CSL, etc. Global top three manufacturers hold a share over 75%.
North America is the largest market, with a share about 45%, followed by Europe, and Asia-Pacific, both have a share about 45 percent.
In terms of product, 500 IU/Vial is the largest segment, with a share over 50%. And in terms of application, the largest application is Hemophilia B, followed by Vitamin K Deficiency, etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Human Prothrombin Complex market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
500 IU/Vial
600 IU/Vial
1000 IU/Vial
Others
Segmentation by application
Hemophilia B
Vitamin K Deficiency
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Takeda
CSL
Grifols
Octapharma
Hualan Biological
Meheco Xinxing Pharma
Key Questions Addressed in this Report
What is the 10-year outlook for the global Human Prothrombin Complex market?
What factors are driving Human Prothrombin Complex market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Human Prothrombin Complex market opportunities vary by end market size?
How does Human Prothrombin Complex break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

Please note: The report will take approximately 2 business days to prepare and deliver.